Should You Buy The Dogs Of The FTSE For 2015? Royal Dutch Shell Plc, GlaxoSmithKline plc, Standard Chartered PLC, Direct Line Insurance Group PLC And Admiral Group plc

Royal Dutch Shell Plc (LON:RDSB), GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN), Direct Line Insurance Group PLC (LON:DLG) and Admiral Group plc (LON:ADM) could all beat the market in 2015.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This is the second part of my two-part series looking at the 10 FTSE 100 stocks that qualify for a UK version of the popular Dogs of the Dow high-yield investment strategy.

The Dogs strategy involves buying the 10 highest-yielding stocks in the index at the start of the year, and then selling them at the end of the year. In the US, the Dogs strategy has beaten the Dow in two of the last three years.

Here are the final five 2015 Dog stocks from the FTSE 100 (if you missed the first five stocks, you can catch up here):

Company

2015 prospective yield

Royal Dutch Shell (LSE: RDSB)

5.9%

GlaxoSmithKline (LSE: GSK)

5.9%

Standard Chartered (LSE: STAN)

6.0%

Direct Line Insurance Group (LSE: DLG)

7.4%

Admiral Group (LSE: ADM)

6.9%

Shell

No-one quite knows how the oil market will behave next year.

However, Shell should be able to afford to ride out the storm, thanks to its huge scale, large gas business and low debt levels.

Although cash flow could come under pressure next year, the firm’s forecast P/E of 9.8 suggests to me that Shell remains a safe income buy.

GlaxoSmithKline

Allegations of bribery and corruption, patent expiries, and falling profits.

It’s been a poor year for Glaxo, but this has left the UK’s largest pharmaceutical firm trading with a prospective yield of nearly 6% and a planned 82p per share capital return in 2015.

Glaxo remains in my portfolio, and on my buy list.

Standard Chartered

Shares in Asia-focused Standard Chartered have fallen by around 35% this year, amid a constant run of downgraded forecasts.

As a result, the bank’s shares trade on a 2015 forecast P/E of just 8.1, which prices in a lot of bad news, in my view. A prospective yield of around 5.9% should also reward patient investors.

Direct Line

Direct Line makes it into the Dogs of the FTSE thanks to a generous special dividend policy, which gives the firm’s shares a prospective yield of 7.4%, the highest in this group.

The fall in motor insurance premiums does seem to be slowing, so 2015 could be a reasonable year for Direct Line.

Admiral

As with Direct Line, it’s important to remember that these insurers’ generous yields are driven by special dividends, which are currently being paid every year, but may not be in the future.

That aside, Admiral’s 2015 forecast P/E of 14.2 reflects the fact that earnings per share are expected to fall by around 8% next year, raising the risk that dividend growth could also stall.

Roland Head owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Dividend Shares

Will the Diageo share price crash again in 2026?

The Diageo share price has crashed 35.6% over one year, making it one of the FTSE 100's worst performers in…

Read more »

Investing Articles

Is Alphabet still one of the best shares to buy heading into 2026?

The best time to buy shares is when other investors are seeing risks. Is that the case with Google’s parent…

Read more »

Investing Articles

Could the Barclays share price be the FTSE 100’s big winner in 2026?

With OpenAI and SpaceX considering listing on the stock market, could investment banking revenues push the Barclays share price higher…

Read more »

Investing Articles

Will the Nvidia share price crash in 2026? Here are the risks investors can’t ignore

Is Nvidia’s share price in danger in 2026? Stephen Wright outlines the risks – and why some might not be…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Growth Shares

I asked ChatGPT how much £10,000 invested in Lloyds shares 5 years ago is worth today? But it wasn’t very helpful…

Although often impressive, artificial intelligence has its flaws. James Beard found this out when he used it to try and…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Did ChatGPT give me the best FTSE stocks to buy 1 year ago?

ChatGPT can do lots of great stuff, but is it actually any good at identifying winning stocks from the FTSE…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Who will be next year’s FTSE 100 Christmas cracker?

As we approach Christmas 2025, our writer identifies the FTSE 100’s star performer this year. But who will be number…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

I asked ChatGPT for an 8%-yielding passive income portfolio of dividend shares and it said…

Mark Hartley tested artificial intelligence to see if it understood how to build an income portfolio from dividend shares. He…

Read more »